Castle Biosciences (CSTL) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $1.03B and a free-cash-flow yield of 2.9%. Over the most recent reported fiscal year, revenue grew 3.7% and free cash flow per share fell 21.8%. Nama's AI scorecard rates it Hold, 5.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Hold · 5.2/10
The sections balance. As of Nov 20, 2026.
Momentum
Lagging · -3.8% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-32.1%
How far the last close sits under the highest price of the past five years.
Market cap
$1.03B
Trailing P/E
—
Price / book
2.1
Price / sales
2.7
FCF yield
2.9%
Dividend yield
—
Gross margin
77.1%
Operating margin
-7.4%
Net margin
-6.1%
Revenue growth (YoY)
+3.7%
Revenue growth (3-yr annual)
+35.9%
EPS growth (YoY)
-237.1%
FCF/share growth (YoY)
-21.8%
Beta
0.9
Exchange
NASDAQ
Sector
Healthcare
Industry
Diagnostics Research
CSTL earnings
Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.14).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 5, 2026
-$0.13
-$0.35
+62.9%
$102.89M
Q2 2026
Jul 30, 2026
-$0.07
-$0.41
+82.9%
$103.55M
Q1 2026
May 6, 2026
-$0.49
-$0.49
+0.0%
$83.68M
Q4 2025
Feb 26, 2026
-$0.08
-$0.26
+69.2%
$87.01M
CSTL analyst price target
Median target $48.50 from 10 analysts, ranging $40.00 – $60.00.
Nama's AI scorecard currently rates Castle Biosciences Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does CSTL report earnings?
Castle Biosciences's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.14.
What is the CSTL price target?
The median analyst price target from 10 analysts is $48.50, with a range of $40.00 – $60.00.
Is CSTL Shariah compliant?
Nama's AAOIFI-style screen reads Castle Biosciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.